BETHESDA, Maryland, Dec. 1, 2016 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that results from the company’s Cancer HTS research indicates that specific ratios of Cannabinoids led to Apoptosis in MDA-MB-231 Breast Cancer cell viability.
Cannabics Pharmaceuticals is currently developing a personalized treatment based upon screening of patients’ biopsy and delivering specified cannabinoid medicine which contains anti-tumor properties. It is believed this technology will enable oncologist and other treating physicians to provide cancer patients with a personalized anti-cancer cannabinoid based therapy.
“We are building a data base of patients and compounds, the screening data and the clinical efficacy will be centralized and in proprietary software,” said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc. “Results from the screening of numerous cancer types will produce new data and new patent applications of compounds with anti-cancer properties.”
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and academic research as well as current clinical studies underway at Rambam Hospital. The Company’s scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids. Cannabics’ vision is to create individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.